-
Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
28 Jan 2025 23:02 GMT
… antidepressants for individuals with major depressive disorder (MDD) with inadequate … therapy for treatment of major depressive disorder in adults. News release … treatment in participants with major depressive disorder (MDD). ClinicalTrials.gov ID …
-
Phase 3 Study Initiated: Osavampator as Adjunctive Therapy for Major Depressive Disorder
28 Jan 2025 16:08 GMT
… adjunctive treatment to antidepressants for major depressive disorder (MDD). Investigators will enroll … antidepressant treatment.1
"Major depressive disorder is a condition that has … of patients suffering from major depressive disorder do not achieve a …
-
A Case of PPD in a Mother With a History of Major Depressive Disorder
28 Jan 2025 02:55 GMT
-
3 Studies on Major Depressive Disorder: Physical, Pharmacologic, and Neuromodulatory Interventions Explored
24 Jan 2025 23:58 GMT
… wide use for treatment of major depressive disorder (MDD) and their efficacy. MDD … of treatment resistant depression and major depressive disorder in the United States. J …
-
Navacaprant Did Not Show Statistically Significant Improvements When Treating Patients With Major Depressive Disorder
23 Jan 2025 18:15 GMT
… when treating patients with major depressive disorder (MDD). Despite the … Placebo in Participants With Major Depressive Disorder
ClinicalTrials.gov ID: … Placebo in Participants With Major Depressive Disorder. ClinicalTrials.gov identifier: NCT06029426 …
-
FDA approves Spravato as monotherapy for adults with major depressive disorder
22 Jan 2025 20:55 GMT
… monotherapy for adults with major depressive disorder who had an inadequate … only monotherapy for adults with major depressive disorder who have had inadequate … for adults with treatment-resistant major depressive disorder. Image: Adobe Stock
“Treatment …
-
Neurocrine Biosciences Amends Strategic Collaboration with Takeda to Develop and Commercialize Osavampator
28 Jan 2025 23:27 GMT
… inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide … studied for the treatment of major depressive disorder, as well as a preclinical …
-
FDA approves J&J’s esketamine as stand-alone depression treatment
28 Jan 2025 23:35 GMT
… to treat depression remains unknown.
Major depressive disorder affects approximately 21 million adults …
-
Virginia Legislation To Legalize Marijuana Sales Clears Committee Votes, With Senate Floor Vote Up Next
28 Jan 2025 23:09 GMT
… disorder (PTSD), treatment-resistant depression, major depressive disorder and traumatic brain injury.
Earlier …
-
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
28 Jan 2025 22:07 GMT
… generalized anxiety disorder (GAD) and major depressive disorder (MDD).
The brokerage also pointed …